Background: Poor response to TB therapy might be attributable to subtherapeutic levels in drug-compliant patients. Pharmacokinetic parameters can be affected by comorbidities or the interaction of drugs with food.
Introduction
The current first-line strategy to treat TB is based on the standardized short-course regimen recommended by the WHO of rifampicin, isoniazid, pyrazinamide and ethambutol, which is usually highly effective. 1 Adherence to therapy has conventionally been achieved through directly observed therapy strategies. 1, 2 Despite the success of these programmes in many TB endemic countries, relapse and acquired drug resistance has not been entirely eliminated. 3 Factors such as high baseline bacillary burden or sputum smear positivity, cavitation, HIV, diabetes mellitus and other underlying diseases have been associated with poorer TB outcome. [4] [5] [6] [7] Recently, experimental and clinical studies have shown that pharmacokinetic (PK) variability expressed in key parameters such as plasma AUC seems to play an important role in the emergence of acquired MDR-TB in in vitro models; inadequate exposure to anti-TB drugs is associated with acquired drug resistance. 8, 9 In prospective clinical studies, impaired PK studies have been related to a suboptimal treatment response, 10, 11 though this is not a universal finding. [12] [13] [14] The PK thresholds for TB drugs used for patients with drugsusceptible TB below which treatment outcome is expected to be poorer have been described; these are sometimes used to guide the application of therapeutic drug monitoring (TDM). 15 The demonstration that individual PK variability could not be predicted by measurable factors, has been used to assert the clinical relevance of individual TDM, 10 which has been employed in some specialized TB centres with laboratories experienced in drug concentration analysis. 15 However, concentrations below the expected range for key drugs in the anti-TB regimen have been frequently found in patients responding well to treatment. 16 An important element of this is understanding the drivers of the wide variability in PK parameters both within and between individuals.
Impaired PK of anti-TB drugs has been previously reported in patients with comorbid HIV 17 or diabetes mellitus, 18 male gender, 19 gastrointestinal disorders 20 or (for isoniazid) fast acetylator status. 14, 21 Several studies suggest that bioavailability of rifampicin and isoniazid is reduced by dosing the TB drugs with meals, 20, 22, 23 prompting recommendations that the drugs should be taken on an empty stomach. However, other studies showed no significant difference in the time for which the serum rifampicin remained above the MIC for Mycobacterium tuberculosis, suggesting that the chemotherapeutic effect is likely to be unaffected. 24 As anti-TB drugs can cause gastrointestinal upset, which may impair adherence to therapy, [25] [26] [27] an adverse effect heightened by taking medication without food, the current official recommendation of the American Thoracic Society, is to provide TB medication with meals if gastrointestinal intolerance persists. 28 However, few studies have evaluated if patients dosing the TB drugs with meals are associated with treatment failure or early relapse.
The aim of this study was to (i) determine the frequency and magnitude of any within-person difference in the PK of rifampicin and isoniazid in a group of patients taking TB treatment on an empty stomach or with food, and (ii) determine the effect upon sputum smear and culture conversion times and end-of-treatment (EOT) and EOT ! 6 month disease outcomes of taking TB treatment predominantly with food or predominantly fasted during the course of treatment.
Patients and methods

Study design, participants and setting
This observational study was conducted in Lima (Peru), from January to December 2012. People diagnosed with pulmonary TB in south Lima (Dirección de Salud-II Lima Sur; regional Ministry of Health) commencing supervised treatment under the directly observed therapy short-course programme of the Peruvian National TB programme (PNTP) were invited to participate at their local healthcentre.
The schedule recommended by PNTP was 6 days per week during the intensive phase (rifampicin, isoniazid, pyrazinamide and ethambutol) and twice a week (rifampicin/isoniazid) during the maintenance phase at the time of the study. The rifampicin dose was 10 mg/kg of body weight and the isoniazid dose was 5 mg/kg of body weight/day during the intensive phase of treatment. Within the PNTP, TB drugs are not available as fixeddose combinations.
Patients who were not sputum smear positive, who were known to have comorbid HIV disease or diabetes mellitus, or were unwilling or unable to give informed consent were excluded from the study.
A semi-structured questionnaire was given to all participants. Personal data, information about their TB disease, gender, age, height (cm) and weight (kg) were recorded and the BMI was calculated. A chest radiograph was performed for all participants and the scored developed by Ralph et al. 29 was used to calculate the severity of pulmonary TB in each particular case.
All patients were given a diet diary (collected at weekly intervals to encourage completion) where they annotated, for each day, whether they had eaten and the kind of food they had eaten in the period beginning 2 h before, during or within 1 h after the drug intake.
At day 30 and 60, blood samples were drawn from each patient at the healthcentre by dedicated staff into 10 mL lithium heparin tubes at three timepoints (2, 4 and 6 h) after the directly observed TB drug intake. On one of these days, patients were required to fast at least 1 h before and 1 h after the drug intake.
Treatment outcome of patients was determined at EOT (by personal examination, chest radiography and conventional culture) and 6 months later by either a personal interview or a phone call.
Laboratory methods
All blood samples were drawn and centrifuged in the healthcentres (centrifugation at 2000 rpm for 10 min) and aliquots of the serum were refrigerated and transported to Universidad Peruana Cayetano Heredia (Lima) and stored at #70 C until batched and transported to the PK laboratory of the Liverpool School of Tropical Medicine. Rifampicin and isoniazid concentrations in each blood sample were determined with validated assays, 19, 30 described in detail in the Supplementary data available at JAC Online.
PK outcome measurements
For each patient, the C max was defined as the highest of the three concentrations measured at 2, 4 and 6 h, and the T max was the timepoint at which the C max occurred. PK parameters were obtained by non-compartmental analysis using the trapezoidal rule and the linear-up-log-down method. MIC data were not available, and no additional analysis of PK/pharmacodynamic parameters was developed. Although an internationally agreed-upon guideline for TDM is lacking, rifampicin C max values were also categorized as normal (.8 mg/L), low (4-8 mg/L) or very low (,4 mg/L) in accordance with previous work. 20, 31 Normal isoniazid C max was defined, by comparison with existing PK data, as 3-5 mg/L after 5 mg/kg daily. 20 Isoniazid PK data were categorized according to Pasipanodya and Gumbo, 32 who established that a C max level of ,2 mg/L after a 300 mg daily dose and a C max level of ,7 mg/L after a 900 mg biweekly dose were regarded as inadequate.
Data analysis
The v 2 test was used for the comparison of proportions and Student's t-test or the Wilcoxon signed rank test for paired samples was used for continuous variables, depending on variable distribution. The percentage of treatment days on which treatment was taken in a fasting state was derived from individuals from their diet diaries, for use as a continuous exposure variable in the outcome analysis. The data were analysed with Stata-13.
Ethics
The study protocol and consent form were approved by the Ethics Committee of the London School of Hygiene and Tropical Medicine (London) and the Institutional Review Boards of the Universidad Peruana Cayetano Heredia (Lima) and the Dirección de Salud-II Lima Sur (regional Ministry of Health, Lima, Peru).
Results
Sixty patients were recruited to the study with a median age of 32.7 (IQR " 23.7-45 years); 34 (56.7%) were male. General characteristics of patients are summarized in Table 1 . The median rifampicin, isoniazid, ethambutol and pyrazinamide dosages received were consistent with those recommended by the PNTP.
Eight patients withdrew from the study before the first blood sample, two additional subjects were withdrawn after a subsequent new diagnosis of HIV and two more changed treatment regimen (one due to resistance and one due to adverse effects), so Rifampicin and isoniazid plasma concentrations in TB patients JAC were also withdrawn. Thus, 48 patients had at least one PK data point and were included in the PK analysis ( Figure 1 ).
Eleven patients could not be included in the treatment outcome follow-up (six had changed therapy after PK sampling because of drug resistance and five abandoned either the therapy or the study). Thirty-seven participants were included in the followup evaluation.
The information on the diet diaries was analysed for the 37 patients with follow-up treatment outcome data. During the intensive phase, patients properly fasted (only drinking water) on a median of 2% of the treatment days (IQR " 1-7.5) and they took the TB drugs with water or any other drink (juice, cereal or carbonated beverages) without solid food a median of 4.5% of the treatment days (IQR " 1-11.5). Throughout the rest of the treatment days, patients consumed some food during drug intake.
During the maintenance phase, patients fasted (only drinking water) with the drug intake a median of 1% of the treatment days (IQR " 0-3) and they took the TB drugs either with water or with a drink without a meal a median of 4% of the treatment days (0-10). Throughout the rest of the treatment days, patients consumed some food during drug intake.
PK results
PK of rifampicin
Overall, median serum rifampicin levels at 2, 4 and 6 h were 3.25, 6.08 and 4.2 mg/L, respectively, during the non-fasting and 6.49, 6.08 and 4.23 mg/L, respectively, during fasting. The individual difference between rifampicin PK during fasting compared with nonfasting was particularly high at 2 h ( Figure 2 ).
Comparing PK parameters within individuals, the median C max and AUC 0-6 were higher during fasting than non-fasting: 7.02 versus 6.59 mg/L (P " 0.054) and 28.64 versus 24.31 mgÁh/L (P " 0.002, Wilcoxon signed rank test), respectively.
Rifampicin C max , when rifampicin was taken in a non-fasting state, was significantly lower in male compared with female patients (6 versus 8.3 mg/L, P " 0.035); however, this effect of gender was not apparent when rifampicin was taken in a fasting state (6.73 versus 7.55 mg/L, P " 0.09).
Though not statistically significant there was also a tendency towards lower rifampicin AUC 0-6 in male compared with female patients with dosing in both the fasting (27.85 versus 31.75 mgÁh/L, P " 0.09) and non-fasting (22 versus 27.27 mgÁh/L, P " 0.08) states.
Effect of fasting on T max
During fasting, T max occurred at 2, 4 or 6 h in 68.8%, 27.1% and 4.2% of patients, respectively. During non-fasting, T max occurred at 2, 4 or 6 h in 34.8%, 56.5% and 8.7%, respectively, a statistically significant delay overall compared with the fasting state T max (P " 0.005, Wilcoxon signed rank test). T max was not associated with gender, age group or dose received (data not shown).
Categorization of C max : adequate versus inadequate levels
When non-fasting, three patients (6.5%) had C max values of ,4 mg/L, 28 (60.9%) had rifampicin levels between 4 and 8 mg/L, and 15 (32.6%) had values regarded as adequate levels for TDM (.8 mg/L). When the blood sampling was done during fasting, 1 patient (2.1%) had a C max value of ,4 mg/L, 30 (62.5%) had levels between 4 and 8 mg/L, and 17 (35.4%) had normal levels (.8 mg/L) ( Figure 3 ). Considering rifampicin AUC 0-6 values ,13 mgÁh/L as low or inadequate levels of AUC 0-24 , as suggested by Pasipanodya et al., 10 13% of patients had a low AUC during fasting compared with 2.1% during non-fasting.
Rifampicin C max correlated with rifampicin dosage received when rifampicin medication was taken with food (Spearman coefficient " 0.37, P " 0.01), but not when rifampicin was taken in the fasting state (Spearman coefficient " 0.15, P " 0.31).
Multivariate analysis
A model was constructed to assess the independent effect of fasting during drug intake, rifampicin T max and gender on the logarithm of rifampicin C max . Rifampicin C max during fasting was found to be 15% higher than rifampicin C max during non-fasting (CI " 1.01-1.30, P , 0.036). C max for females was 20% higher than Requena-Méndez et al.
for males (P " 0.03). The effect of T max did not influence the C max (T max 4 h " 0.98, P " 0.9; T max 6 h " 1.11, P " 0.676) ( Table 2 ). A further model was constructed to assess the independent effect of fasting during drug intake, the rifampicin T max and gender on the logarithm of rifampicin AUC 0-6 .
Rifampicin AUC 0-6 during fasting was found to be 14% higher than rifampicin AUC 0-6 during non-fasting (CI " 1.01-1.28, P , 0.02). Rifampicin AUC 0-6 for females was 20% higher than for males (P " 0.027). When rifampicin T max occurred at 4 h, rifampicin AUC 0-6 was reduced by 20% (P " 0.002) and when it occurred at 6 h, the rifampicin AUC 0-6 decreased by 50% (P , 0.001), as compared with a rifampicin T max of 2 h.
PK of isoniazid
Overall, median serum isoniazid levels at 2, 4 and 6 h were 3.27, 1.96 and 0.92 mg/L, respectively, during non-fasting and 4.54, 1.19 and 0.75 mg/L, respectively, during fasting. The individual difference between isoniazid PK during fasting compared with nonfasting was particularly high at 2 h (Figure 4 ).
There were significant differences in the C max during nonfasting (median 3.51 mg/L) compared with fasting (4.54 mg/L) (P , 0.001, Wilcoxon signed rank test). The AUC 0-6 was 12.11 mgÁh/L during non-fasting versus 13.31 mgÁh/L during fasting (P " 0.001).
Isoniazid C max in men was not different to isoniazid C max in women, whether fasted (4.21 versus 4.88 mg/L; P " 0.21) or not (3.29 versus 4.41 mg/L, P " 0.08). Similarly, isoniazid AUC 0-6 did not differ between males and females either with fasting (13.21 versus 15.13 mgÁh/L, P " 0.28) or non-fasting dosing conditions (12.08 versus 12.65 mgÁh/L, P " 0.36). Isoniazid C max was not affected by presence of intestinal parasites, age group or BMI (data not shown).
Effect of fasting on isoniazid T max
T max occurred at 2 h in 80.4% and 95.8% of patients during nonfasting and fasting, respectively, at 4 h in 17.4% and 2.1% of patients during non-fasting and fasting, respectively, and at 6 h in 2.2% and 2.1% of patients during non-fasting and fasting, respectively; a statistically significant delay due to non-fasting (P " 0.023, Wilcoxon signed rank test).
T max was not associated with gender, age group, intestinal parasitic infection or dose received (data not shown) regardless of fasting condition.
During non-fasting, 7 patients (15.2%) had C max values of ,2 mg/L and 39 (84.8%) had values regarded as adequate levels. When isoniazid was taken in a fasting condition, 3 (6.3%) had C max values of ,2 mg/L and 45 (93.8%) had adequate levels (.2 mg/L) ( Figure 5 ). However, considering isoniazid AUC 0-6 values ,52 mgÁh/L as low or inadequate levels of AUC 0-24 , as suggested by Pasipanodya et al., 10 100% of patients had a low AUC during fasting compared with 95% during non-fasting (P " 0.162).
A model was constructed to assess the independent effect of gender, isoniazid dose received and the effect of fasting during drug intake on the logarithm of isoniazid C max (Table 3) .
The isoniazid dose received had an effect upon the isoniazid levels (1.26, P " 0.038). Moreover, isoniazid exposure during fasting was found to be 14% higher than during non-fasting (CI " 1.02-1.28, P , 0.001) ( Table 3) . No other variables significantly influenced the model. A further model was constructed to assess the independent effect of gender, isoniazid T max and the effect of fasting during drug intake on the isoniazid AUC 0-6 .
Isoniazid AUC 0-6 was found to be 22% higher during fasting than non-fasting (CI " 1.09-1.38, P , 0.001). When isoniazid T max occurred at 6 h, isoniazid AUC 0-6 decreased by 47% (P " 0.013). The remaining variables did not significantly influence the model. All 37 patients evaluated at the EOT were considered cured. Thirty-seven patients were evaluated at 6 months after the EOT, and 36 were cured and 1 had relapsed 2 months after having finished the therapy. This 47-year-old male had successfully completed first-line TB therapy with clinical and radiological improvement; although a fibrotic right apical scar was seen at EOT, TB culture at this time was negative. Two months later he restarted TB therapy after an early microbiology-confirmed relapse with a positive culture was diagnosed. The Rx Ralph score of this patient had been 42 (median Rx Ralph score " 22.6). He had fasted 16% of the time during the intensive phase and had not fasted on any occasion in the maintenance phase.
For the 37 subjects with treatment outcome data, neither the Rx score nor consumption of food with drug intake nor PK of rifampicin or isoniazid was associated with a poorer treatment outcome (data not shown).
Discussion
The results of this study demonstrate that rifampicin in particular and isoniazid PK (C max , T max and AUC 0-6 ) were significantly affected by the intake of the drug with food, as has been shown 60 patients 48 patients with at least 1 PK data 46 patients with 2 PK data and followed-up 37 patients followed until EOT. All of them were considered cured. Rifampicin and isoniazid plasma concentrations in TB patients JAC previously. 33 However, the effect of food was not large (15% reduction in C max for isoniazid and rifampicin overall) and was highly variable between individuals, with some participants achieving higher exposure on non-fasted than fasted days.
A delay in rifampicin absorption was observed and the median T max occurred at 4 h instead of 2 h among those who took drug with food. By excluding interindividual variability, this intra-individual PK analysis demonstrated the interaction of the food during drug intake in the absorption delay (T max ) and in the AUC 0-6 , which has been corroborated in the multivariate analysis. As has been suggested before and further confirmed by our data here, slower absorption leads to lower plasma concentrations. 34 When rifampicin was ingested with food, low levels of rifampicin were observed in more than half of patients although very low levels (,4 mg/L) were only observed in ,10% of patients. Lower levels of rifampicin C max and lower rifampicin AUC 0-6 were demonstrated among non-fasted men compared with women. Although this was not observed when the drug was taken on an empty stomach, in multivariate analysis gender influenced the PK of rifampicin regardless of fasting status. These gender differences give cause for consideration of whether dosing recommendations warrant review, though in the absence of a demonstrable impact upon treatment outcome, this is probably premature. 35 Isoniazid T max occurred at 2 h regardless of fasting status although the PK parameters (C max ) were higher in the fasting blood Requena-Méndez et al.
sampling; other studies have suggested that food causes an absorption delay and reduces the C max . 36 It has been suggested that isoniazid T max might sometimes occur earlier than 2 h and we would not have captured this as our earliest sampling timepoint was 2 h. The multivariate analysis also demonstrated the effect of fasting on increasing the exposure to isoniazid.
In both univariate and multivariate analysis, isoniazid AUC 0-6 and isoniazid C max did not differ by gender in either the fasted or non-fasted state.
A factor that could influence the variability of rifampicin and isoniazid PK is that the study was carried out under real-life field conditions and not in the controlled environment of a dedicated PK unit, though conversely this design generates more translatable data as patients are doing what they do every day. Another strength of this study is that we were able to eliminate the confounding effect of interindividual variability upon interpretation of the effect of food, because patients had blood sampling under both fasting and under non-fasting conditions, and a corresponding matched analysis was performed.
It is usually recommended that rifampicin and isoniazid are to be given on an empty stomach whenever possible, based on previous PK studies. 37 However, few studies have evaluated if patients dosing the TB drugs with meals are associated with treatment failure or early relapse. In the US Public Health Service TB Trial-22 in which patients received rifapentine/isoniazid, patients receiving medication under fed conditions were significantly associated with treatment failure or relapse although patients were receiving isoniazid and rifapentine instead of rifampicin. 8 However, the exquisite dependence of rifapentine PK is well recognized so these data are not directly relevant.
A secondary aim of our study was to determine if taking TB drugs with meals is associated with a poor response to treatment, an impact that could be hypothesized might result from lower drug exposure. In the event participant diet diaries demonstrated the real-world reality in that most patients did not fast on most days around the time of drug intake in either the intensive or maintenance phase. As a result the exposure risk (taking TB drugs in an unfasted state) was recorded for 98%-99% of patients; furthermore, there was only one recorded adverse outcome due to an early relapse, resulting in such low power as to render an analysis futile. A limitation of our study design is that follow-up for relapses was short at 6 months, so later relapses would not have been detected. We did not record reported side effects and were thus unable to determine whether fasting increased the likelihood, a rifampicin C max during fasting was 15% higher than rifampicin C max during non-fasting; and b rifampicin C max in females was 20% higher than rifampicin C max in males.
Rifampicin and isoniazid plasma concentrations in TB patients JAC mitigation of which is the reason patients choose not to take their medicines on an empty stomach.
However, according to the literature, other factors may also influence the treatment response. As a way of example, the effect of the combination therapy or the unknown determinants of drug efficacy at a cellular level could influence positively the treatment outcome and despite low serum rifampicin or isoniazid concentrations, these facts may contribute to a good treatment outcome.
Moreover, although we have observed 'subtherapeutic' C max levels of rifampicin in $30% of patients, only one patient was finally reported to have a bad treatment outcome. Interestingly when we calculate low rifampicin exposure through AUC parameters, we observe that only 13% had low AUC exposure. Therefore, further investigation is needed to ascertain whether a review of the purported normal rifampicin C max of .8 mg/L is warranted and if the threshold proposed by Pasipanodya et al.
10 from hollow fibre model studies is a suitable predictor of treatment outcome. Other studies have demonstrated that an increase in the dose of rifampicin, which is evidently well tolerated, has led to a better treatment outcome. 38 Therefore, if we assume a higher median concentration in those patients who received a higher dose, we could accordingly consider that there is a correlation between the concentration and the treatment outcome.
Concerning isoniazid, most patients had normal C max values. In contrast, if we consider the threshold of 52 mgÁh/L suggested by Pasipanodya et al., 10 again from the hollow fibre model, most patients would be classified as having had a low isoniazid exposure. A main limitation of considering the AUC as a marker of drug exposure is the fact that we had to calculate the AUC 0-6 instead of AUC 0-24 as suggested by Pasipanodya et al. 10 due to the limited sample points in our study.
The study was not designed to prove definitively whether poorer outcome was associated with rifampicin or isoniazid exposure. In this underpowered subanalysis, the treatment outcome was not influenced by impaired PK (rifampicin or isoniazid) or by difference in the intake of TB drugs with food. However, the small number of poor treatment outcomes means that this could represent a type II error. However, it could also be that the effect of food on plasma PK is insufficiently large to impact upon the response to treatment either because there are other factors that dominate or because the bit of redundancy in multidrug therapy compensates for this. Moreover, we had hoped to be able to tease out a gradient of different categories of how often patients took their drugs fasting (e.g. 'most', 'some', 'rarely') and compare outcomes ('treatment outcomes' and 'conversion times'), but almost all were 'rarely' fasting so this was not possible.
It seems clear that lower serum concentrations, particularly with rifampicin can still be part of an effective therapy regimen in most patients. However, we could not accurately measure the effect of how the combination therapy might have positively influenced the treatment outcome. Although this synergistic effect can potentially be measured through a microdilution chequerboard assay, 39 drug susceptibility testing is done individually for each drug. 40 Thus, any effect of a low rifampicin or isoniazid concentration might be overcome by the effect of the other agents and thus not directly influence treatment outcome.
It should be added that it is unclear what the crucial determinant of drug efficacy at the cellular level is and, if so, what the minimum drug exposure (measured in plasma) needs to have a high probability of efficacy.
Although TDM is neither widely used nor recommended during TB treatment, it is increasingly stated that abnormal TB drug PK may adversely influence outcomes, with treatment failure, relapse or death, prolonged infectiousness, and the development of acquired drug resistance. 41, 42 In addition, TDM might contribute not only to the identification of patients with low levels of rifampicin or isoniazid, but also to a shrinking of the time to response and the duration of treatment. 43 A 2 and 6 h post-dose sampling strategy may facilitate the analysis of both agents and it seems reasonable and practical.
Regarding the interpretation of the TDM results, it is very complex to define the endpoints of thresholds of 'therapeutic', as the disease in humans is much more complex than in vitro models and more variable than the situation produced in animal models. Interpretation of the proportional difference: isoniazid C max during fasting was 14% higher than isoniazid C max during non-fasting.
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Conclusions
Rifampicin in particular and isoniazid PK (both C max and AUC 0-6 ) were significantly affected by the intake of the drug with food in a proportion of patients. A clear relationship between the PK parameters and treatment outcome was not demonstrated.
